Tags

Type your tag names separated by a space and hit enter

Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials.
Int J Clin Pract. 2013 Sep; 67(9):834-42.IJ

Abstract

OBJECTIVES

The presumed superiority of moxifloxacin for the treatment of complicated skin and skin structure infections (cSSSIs) is based on laboratory data, but has not yet been established on clinical grounds. The aim of this meta-analysis was to evaluate the efficacy and safety of sequential intravenous (i.v.)/oral (p.o.) moxifloxacin monotherapy for the treatment of cSSSIs.

METHODS

Randomised controlled trials (RCTs) published prior to November 2012 were systematically retrieved from PubMed, MEDLINE, EMBASE, ScienceDirect, ClinicalTrials.gov and the Cochrane Central Register of Controlled Trials. Finally, a meta-analysis of all RCTs eligible for inclusion criteria was performed.

RESULTS

Three studies that enrolled 2255 patients were included in the meta-analysis. There were no statistically significant differences between patients given moxifloxacin and those given other antibiotics with regard to clinical success rate [1667 patients, odds ratio (OR) = 0.83, 95% confidence interval (CI) 0.63 to 1.09, p = 0.18], bacteriological success rate (bacteriological success rates: 1502 patients, OR = 0.90, 95% CI 0.68-1.18, p = 0.45) or mortality (2207 patients, OR = 1.96, 95% CI 0.79-4.88, p = 0.15). Significantly, more overall adverse events (AEs) were associated with the use of moxifloxacin than with other antibiotics (2207 patients, OR = 1.21, 95%CI 1.00-1.45, p = 0.04). However, there was no statistically significant difference in the occurrence of drug-related AEs, serious AEs or serious drug-related AEs between patients given moxifloxacin and those given other antibiotics.

CONCLUSION

Sequential i.v./p.o. moxifloxacin monotherapy is an effective and relatively safe option for the treatment of cSSSIs. Other benefits of moxifloxacin may make it a more viable option compared with the currently used regimens.

Authors+Show Affiliations

Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

23952463

Citation

Chen, F, et al. "Sequential Intravenous/oral Moxifloxacin Monotherapy for Complicated Skin and Skin Structure Infections: a Meta-analysis of Randomised Controlled Trials." International Journal of Clinical Practice, vol. 67, no. 9, 2013, pp. 834-42.
Chen F, Zheng N, Wang Y, et al. Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2013;67(9):834-42.
Chen, F., Zheng, N., Wang, Y., Wen, J. L., Tu, W. F., Du, Y. Q., & Lin, J. M. (2013). Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials. International Journal of Clinical Practice, 67(9), 834-42. https://doi.org/10.1111/ijcp.12174
Chen F, et al. Sequential Intravenous/oral Moxifloxacin Monotherapy for Complicated Skin and Skin Structure Infections: a Meta-analysis of Randomised Controlled Trials. Int J Clin Pract. 2013;67(9):834-42. PubMed PMID: 23952463.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials. AU - Chen,F, AU - Zheng,N, AU - Wang,Y, AU - Wen,J L, AU - Tu,W F, AU - Du,Y Q, AU - Lin,J M, PY - 2012/12/28/received PY - 2013/03/13/accepted PY - 2013/8/20/entrez PY - 2013/8/21/pubmed PY - 2014/1/22/medline SP - 834 EP - 42 JF - International journal of clinical practice JO - Int J Clin Pract VL - 67 IS - 9 N2 - OBJECTIVES: The presumed superiority of moxifloxacin for the treatment of complicated skin and skin structure infections (cSSSIs) is based on laboratory data, but has not yet been established on clinical grounds. The aim of this meta-analysis was to evaluate the efficacy and safety of sequential intravenous (i.v.)/oral (p.o.) moxifloxacin monotherapy for the treatment of cSSSIs. METHODS: Randomised controlled trials (RCTs) published prior to November 2012 were systematically retrieved from PubMed, MEDLINE, EMBASE, ScienceDirect, ClinicalTrials.gov and the Cochrane Central Register of Controlled Trials. Finally, a meta-analysis of all RCTs eligible for inclusion criteria was performed. RESULTS: Three studies that enrolled 2255 patients were included in the meta-analysis. There were no statistically significant differences between patients given moxifloxacin and those given other antibiotics with regard to clinical success rate [1667 patients, odds ratio (OR) = 0.83, 95% confidence interval (CI) 0.63 to 1.09, p = 0.18], bacteriological success rate (bacteriological success rates: 1502 patients, OR = 0.90, 95% CI 0.68-1.18, p = 0.45) or mortality (2207 patients, OR = 1.96, 95% CI 0.79-4.88, p = 0.15). Significantly, more overall adverse events (AEs) were associated with the use of moxifloxacin than with other antibiotics (2207 patients, OR = 1.21, 95%CI 1.00-1.45, p = 0.04). However, there was no statistically significant difference in the occurrence of drug-related AEs, serious AEs or serious drug-related AEs between patients given moxifloxacin and those given other antibiotics. CONCLUSION: Sequential i.v./p.o. moxifloxacin monotherapy is an effective and relatively safe option for the treatment of cSSSIs. Other benefits of moxifloxacin may make it a more viable option compared with the currently used regimens. SN - 1742-1241 UR - https://www.unboundmedicine.com/medline/citation/23952463/Sequential_intravenous/oral_moxifloxacin_monotherapy_for_complicated_skin_and_skin_structure_infections:_a_meta_analysis_of_randomised_controlled_trials_ L2 - https://doi.org/10.1111/ijcp.12174 DB - PRIME DP - Unbound Medicine ER -